FIELD: medicine.
SUBSTANCE: inventions group relates to methods for treating an autoimmune disease using allogeneic T-cells. The methods are based on administering to the subject allogeneic cytotoxic T cells (CTL) expressing a T cell receptor that specifically binds to an Epstein-Barr virus (EBV) peptide present on MHC class I, where MHC class I is encoded by an HLA allele that is present in subject.
EFFECT: inventions make it possible to carry out the treatment of multiple sclerosis, in particular, primary progressive or secondary progressive multiple sclerosis.
26 cl, 1 dwg, 1 tbl, 5 ex
| Title | Year | Author | Number |
|---|---|---|---|
| METHODS FOR TREATING MULTIPLE SCLEROSIS USING AUTOLOGOUS T CELLS | 2018 |
|
RU2769474C2 |
| IMMUNOTHERAPY METHODS | 2017 |
|
RU2756276C2 |
| METHODS OF EXPANSION OF ANTIGEN-SPECIFIC CAR-T-CELLS, COMPOSITIONS AND THEIR USE | 2019 |
|
RU2800920C2 |
| METHODS FOR SELECTING A T-CELL LINE AND ITS DONOR FOR ADOPTIVE CELL THERAPY | 2015 |
|
RU2734784C2 |
| METHODS OF EX VIVO EXPANSION OF NATURAL KILLER CELLS AND THEIR USE | 2019 |
|
RU2814083C2 |
| YEAST-BASED IMMUNOTHERAPEUTIC COMPOSITIONS WITH BRACHYURY | 2012 |
|
RU2690180C2 |
| METHODS OF MULTIPLE MYELOMA AND PLASMA CELL LEUKEMIA TREATMENT BY T-CELL THERAPY | 2016 |
|
RU2743381C2 |
| IMMUNOTHERAPEUTIC COMPOSITIONS BASED ON YEAST WITH BRACHYURY | 2012 |
|
RU2619850C2 |
| NEIL3 PEPTIDES AND VACCINES INCLUDING SAME | 2010 |
|
RU2600888C2 |
| METHOD AND SYSTEMS FOR PREDICTION OF HLA CLASS II-SPECIFIC EPITOPES AND CD4+ T-CELL CHARACTERIZATION | 2019 |
|
RU2826261C2 |
